IN8bio Inc. (6JH0)
XSTU 
Summary
6JH0 Chart
IN8bio (INAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for IN8bio (INAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
IN8bio Inc. (6JH0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has IN8bio Inc. ever had a stock split?
IN8bio Inc. Profile
| Biotechnology Industry | Healthcare Sector | Tai-Wei CEO | XSTU Exchange | US45674E2081 ISIN |
| US Country | 18 Employees | - Last Dividend | 6 Jun 2025 Last Split | 30 Jul 2021 IPO Date |
Overview
IN8bio, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing and commercializing gamma-delta T cell therapies for the treatment of various cancers. Originally founded as Incysus Therapeutics, Inc., the company underwent a name change to IN8bio, Inc. in August 2020, marking a new chapter in its mission to combat cancer. With headquarters in New York, New York, and established in 2016, IN8bio, Inc. has been at the forefront of developing innovative cancer treatments, aiming to offer new hope and solutions for patients battling this challenging disease.
Products and Services
INB-200: This is IN8bio’s lead product candidate, currently in a Phase I clinical trial. INB-200 is a genetically modified autologous gamma-delta T cell therapy designed specifically for the treatment of glioblastoma and solid tumors. By leveraging the unique properties of gamma-delta T cells, INB-200 aims to offer a novel approach to targeting and eliminating cancer cells.
INB-100: Another innovative product candidate from IN8bio, INB-100 is an allogeneic therapy in Phase I clinical trial. It is developed to treat patients with acute leukemia who are undergoing hematopoietic stem cell transplantation. This approach represents a promising advancement in the treatment of acute leukemia, potentially improving outcomes for patients undergoing this intensive therapy.
INB-400: Currently in a Phase 2 clinical trial, INB-400 is designed to treat newly diagnosed glioblastoma multiforme (GBM). This product candidate is part of IN8bio’s ongoing commitment to addressing this highly aggressive form of brain cancer, with the aim of improving survival and quality of life for patients diagnosed with GBM.
INB-300, INB-410, and INB-500: These product candidates are in the preclinical phase and are being developed for the treatment of various solid tumor cancers. Though still in early stages, these therapies underscore IN8bio’s dedication to expanding its portfolio of cancer treatments, with the potential to address a wider range of solid tumor indications in the future.
